CA-LANDMARK-WORLDWIDE
16.9.2021 20:02:03 CEST | Business Wire | Press release
Landmark (Landmark Worldwide ), established in 1991, celebrates its 30th anniversary with more than three million people across the globe having been positively and powerfully contributed to and empowered by its programs. Marking a related anniversary, it was 50 years ago that the ideas that grew into Landmark were born with the delivery of the first est Training in 1971.
As the leader in the personal and professional growth, training and development industry, Landmark’s programs and ideas have empowered people for five decades to dramatically elevate the quality of their lives and, in addition, to impact the areas of their lives that matter most to them.
Marketdata Enterprises, Inc., publishers of the definitive report on the personal development industry in the United States, stated in their 2021 report:
- “Landmark was named one of the top training and development companies in the world by HR.com/James McNeil.”
- “Landmark is recognized for having one of the best faculty bodies in the business,” and many professionals “in the personal development and coaching industries got their start by participating in Landmark’s programs.”
- Landmark is unique in the industry as the “sole program provider of ontological transformation … a transformation in being – a breakthrough that results in immediate, lasting, and dramatic shifts in people’s effectiveness and quality of life.”
50 years ago, Werner Erhard’s est Training launched the personal development industry and the beginning of what has since become the business and life coaching industry. Many of his concepts have earned a lasting place in mainstream culture, business and academia. As TIME magazine recognized, “The American obsession with transformation isn’t new. It’s about as old as the nation, but it was Werner Erhard ... who created the first modern transformation when he founded est seminars in 1971.”
Erhard retired the est Training and launched a new course, The Forum, in 1985. Erhard’s ideas (as expressed in his programs) are examined in detail by two scholars in the best-selling book, Speaking Being : Werner Erhard, Martin Heidegger, and a New Possibility of Being Human.
Described as “one of the most incisive and insightful thinkers of our generation" by David Eagleman, Ph.D., Stanford University neuroscientist and New York Times bestselling author, Erhard has committed the majority of his intellectual efforts over the past three decades to the academic world. With his colleagues, he is writing university-level curricula and teaching and lecturing at universities including the UCLA Anderson School of Management, the United States Air Force Academy, Stanford University, Harvard University, Yale University, Dartmouth College, and Erasmus University.
Today, Landmark continues to make its programs available throughout the world, including having launched virtually all of its more than 50 programs online. Landmark has been and continues to be endorsed by thousands of renowned leaders worldwide, including CEOs of global corporations, widely respected academics, and internationally recognized humanitarians.
“What greatly impressed me with regard to Landmark is it gives people a hands-on access to altering the culture of an organization and to effect significant change in a surprisingly short period of time.”
~ Michael C. Jensen, Jesse Isidor Straus Professor of Business Administration, Emeritus at Harvard University
“Winning a gold medal at the Olympics was extraordinary and, when I did The Landmark Forum, I realized I could have that same level of accomplishment, fulfillment, and joy in every part of my life.”
~ Natalie Cook, Olympic Gold Medalist
“As a person whose life is about global issues, I can’t think of a more effective training program. One of the most valuable results I got was the ability to deal with intractable global problems without getting discouraged. As a result of participating in Landmark, individuals gain the tools to go out into the world and make things happen.”
~ Dr. Charles McNeill, Senior Policy Advisor, United Nations Environment Programme
“I have yet to see anything else that has such a positive impact on people’s ability to relate, communicate, and perform as Landmark.”
~ Paul Fireman, Founder and former Chairman/CEO of Reebok International, Ltd. USA
Landmark’s global management consulting firm and subsidiary, Vanto Group was named one of America’s Best Management Consulting Firms by Forbes Magazine for two consecutive years – 2020 and 2021. In addition, Landmark is the primary catalyst for participants creating more than 150,000 non-profit and pro bono projects, benefiting individuals, organizations, and communities around the world. A few examples include:
- Special Spectators (for which founder, Blake Rockwell was named a CNN Hero) has had a significant impact on tens of thousands of seriously ill children, their siblings and parents by giving them a VIP access game day experience at more than 50 major colleges and universities.
- Plant a Million Trees: Gashaw Tahir founded an NGO called Greenland Development Foundation that planted more than a million trees in Ethiopia and, in the process, put more than 450 young people to work, giving them not only a sense of dignity, but the ability to see a future in Ethiopia.
- R U OK? Day : A suicide prevention project that has been embraced by the entire country of Australia.
Landmark acknowledges and thanks the more than three million people who have participated in its work and the difference they make in their own lives, in the lives of others, and throughout the world.
For more information about Landmark and its programs, visit www.landmarkworldwide.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210916005243/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
